Friday, 29 March 2024


Takeda gets Japan's nod for multiple sclerosis injection

29 September 2015 | Regulatory | By BioSpectrum Bureau

Takeda gets Japan's nod for multiple sclerosis injection

Takeda Pharmaceutical has a obtained new drug application approval for Copaxone Subcutaneous Injection

Takeda Pharmaceutical has a obtained new drug application approval for Copaxone Subcutaneous Injection

Singapore: Japan based Takeda Pharmaceutical has a obtained new drug application approval for Copaxone Subcutaneous Injection 20 mg Syringe (generic name: glatiramer acetate), for the treatment of multiple sclerosis, from the Japanese Ministry of Health, Labour and Welfare.

Developed by Teva Pharmaceutical, Copaxone is a subcutaneous injection administered once daily to prevent the relapse of multiple sclerosis.

In Japan, glatiramer acetate was developed as an unapproved new drug by Teva Pharmaceutical, a wholly owned subsidiary of Teva, at the request of the Japanese Ministry of Health, Labour and Welfare. In March, 2013, Takeda and Teva signed a licensing agreement in which Teva granted Takeda the right to commercialize glatiramer acetate in Japan.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account